We first examined the interaction of ZHX2 and p65 in breast cancer by endogenous IP with ZHX2 or p65 antibody in two TNBC cells (MDA-MB-231 and 468) (Figure 4—figure supplement 1A, B), we did not find consistent and robust binding between ZHX2 and p65 as we observed in ccRCC. This evidence concerns the gene ZHX2 and nonpapillary renal cell carcinoma.